Menu Search
Equities

SciBase Holding AB (publ)

  • Add to watchlist
  • Add to portfolio
  • Add an alert
5J3:MUN

SciBase Holding AB (publ)

Actions
  • Price (EUR)0.0264
  • Today's Change0.00 / 0.00%
  • Shares traded5.00k
  • 1 Year change-13.44%
  • Beta0.6339
Data delayed at least 15 minutes, as of Feb 11 2026 07:02 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

SciBase Holding AB (publ) is a Sweden-based company engaged in the medical equipment industry. The Company specializes in the manufacture of point of care device, called Nevisense, which is aimed to detect of malignant melanoma. Nevisense analyze suspicious lesions by using Electrical Impedance Spectroscopy (EIS) which is applied as an electrical signal to the skin. SciBase Holding AB (publ) specializes in early detection and prevention in dermatology. The Company develops and commercializes Nevisense, a point-of-care platform that combines AI (artificial intelligence) and advanced EIS technology to elevate diagnostic accuracy, ensuring proactive skin health management. SciBase Holding AB (publ) combines advanced EIS technology with AI to empower healthcare professionals by improving diagnostic precision, facilitating disease monitoring, and enabling early detection of skin cancer.

  • Revenue in SEK (TTM)36.58m
  • Net income in SEK-90.39m
  • Incorporated2008
  • Employees34.00
  • Location
    SciBase Holding AB (publ)Landsvagen 39SUNDBYBERG 172 63SwedenSWE
  • Phone+46 841062000
  • Fax+46 86152224
  • Websitehttps://scibase.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.